Overview
- Researchers harmonized clinical, genomic and methylation data from three medulloblastoma trials totaling nearly 900 pediatric patients.
- The integrated analysis defined four actionable treatment groups using predictors that include G3/G4 subdivision by chromosome changes, methylation subgroup and MYC amplification.
- Retrospective results indicate about 40% of patients could receive lower craniospinal radiation and most could receive less chemotherapy with comparable survival outcomes.
- St. Jude introduced the MB‑meta web portal, a point‑and‑click tool that generates predicted survival curves based on selected clinical, demographic and molecular features.
- Giles Robinson is launching a prospective trial to validate the risk‑based approach, and portal‑driven exploration identified two novel KBTBD4 mutation subgroups for further study.